Synaptic Dysfunction in Progressive Supranuclear Palsy

Synaptic Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive Supranuclear Palsy (PSP) is a 4R tauopathy characterized by progressive supranuclear gaze palsy, axial rigidity, postural instability, and cognitive decline. Synaptic dysfunction represents a critical pathological mechanism in PSP, underlying both the motor and cognitive manifestations of the disease. The accumulation of hyperphosphorylated 4R tau in synaptic compartments disrupts neurotransmission, impairs vesicle dynamics, and leads to progressive synaptic failure across multiple brain regions.

Unlike Alzheimer's Disease, where amyloid-beta initiates synaptic toxicity, PSP demonstrates tau-driven synaptic impairment as the primary pathological mechanism. The pattern of synaptic vulnerability in PSP reflects the characteristic distribution of tau pathology, with early and severe involvement of brainstem synaptic circuits, basal ganglia nuclei, and the cerebral cortex[@taubased2022][@tau2022].

Pattern of Synaptic Loss in PSP

Regional Distribution

Synaptic loss in PSP follows a characteristic anatomical pattern that correlates with clinical phenotype:

Synaptic Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive Supranuclear Palsy (PSP) is a 4R tauopathy characterized by progressive supranuclear gaze palsy, axial rigidity, postural instability, and cognitive decline. Synaptic dysfunction represents a critical pathological mechanism in PSP, underlying both the motor and cognitive manifestations of the disease. The accumulation of hyperphosphorylated 4R tau in synaptic compartments disrupts neurotransmission, impairs vesicle dynamics, and leads to progressive synaptic failure across multiple brain regions.

Unlike Alzheimer's Disease, where amyloid-beta initiates synaptic toxicity, PSP demonstrates tau-driven synaptic impairment as the primary pathological mechanism. The pattern of synaptic vulnerability in PSP reflects the characteristic distribution of tau pathology, with early and severe involvement of brainstem synaptic circuits, basal ganglia nuclei, and the cerebral cortex[@taubased2022][@tau2022].

Pattern of Synaptic Loss in PSP

Regional Distribution

Synaptic loss in PSP follows a characteristic anatomical pattern that correlates with clinical phenotype:

| Brain Region | Synaptic Marker Reduction | Clinical Correlation |
|--------------|---------------------------|---------------------|
| Substantia nigra pars compacta | 40-55% synaptophysin | Dopaminergic dysfunction, parkinsonism |
| Globus pallidus internus | 35-50% synaptophysin | Axial rigidity, falls |
| Subthalamic nucleus | 30-45% | Movement initiation deficits |
| Superior colliculus | 45-60% | Vertical gaze palsy |
| Oculomotor nucleus | 40-55% | Eye movement abnormalities |
| Frontal cortex | 25-40% | Executive dysfunction |
| Dentate nucleus (cerebellum) | 30-45% | Gait ataxia |

The severity of synaptic loss in the brainstem oculomotor regions directly correlates with the presence and severity of vertical gaze palsy, one of the hallmark features of PSP[@brainstem2017][@oculomotor2018].

Quantitative Neuropathology Studies

Postmortem studies demonstrate significant reductions in synaptic markers:

• Synaptophysin: 35-50% reduction in affected basal ganglia regions compared to age-matched controls[@synaptic2017]
• Synapsin I: 30-45% reduction in the substantia nigra[@synapsin2019]
• PSD-95: 25-40% reduction in the frontal cortex[@postsynaptic2018]
• SV2 (Synaptic Vesicle Protein 2): 35-55% reduction in brainstem motor nuclei[@alterations2017]

Comparison with Other Tauopathies

| Feature | PSP | Corticobasal Syndrome | Alzheimer's Disease |
|---------|-----|----------------------|---------------------|
| Primary driver | 4R tau | 4R tau | Aβ + 3R/4R tau |
| Brainstem involvement | Very early, severe | Moderate | Late, mild |
| Basal ganglia vulnerability | Severe | Severe | Moderate |
| Cortical synaptic loss | Moderate (25-40%) | Severe (30-50%) | Severe (25-65%) |
| Hippocampal involvement | Mild | Mild | Severe |

Key distinguishing features:

• PSP demonstrates earlier and more severe brainstem synaptic involvement than CBS or AD[@comparative2018]
• The oculomotor nucleus and superior colliculus show particularly severe synaptic loss in PSP
• Cortical synaptic loss in PSP is less severe than in AD, correlating with the different cognitive profiles

Pre-synaptic Changes in PSP

Tau Accumulation in Presynaptic Terminals

Pathological 4R tau accumulates in presynaptic boutons in PSP brains:

• Hyperphosphorylated tau localizes to presynaptic terminals in affected brain regions[@tau2016]
• Tau disrupts the actin cytoskeleton essential for vesicle trafficking
• Pathological tau interferes with synapsin I phosphorylation, affecting vesicle mobilization
• The presynaptic compartment shows more severe tau burden than postsynaptic structures in early PSP[@presynaptic2017]

Synaptic Vesicle Cycle Impairment

Presynaptic terminals in PSP exhibit multiple abnormalities in vesicle dynamics:

Molecular Mechanisms

Voltage-gated calcium channel dysfunction:

• P/Q-type and N-type calcium channel expression is altered in PSP substantia nigra[@voltagegated2020]
• Calcium dysregulation promotes vesicle depletion during sustained activity
• Impaired calcium buffering contributes to excitotoxicity

• Tau interacts with syntaxin and SNAP-25 in PSP brains[@tau2017]
• These interactions reduce the efficiency of vesicle fusion
• Reduced release probability at corticostriatal and corticobulbar synapses

• Tau disrupts kinesin-mediated mitochondrial trafficking to synaptic terminals[@tau2018]
• Energy depletion impairs vesicle cycling
• Synaptic terminals become vulnerable to oxidative stress

Electrophysiological Evidence

Electrophysiology studies in PSP models reveal:

• Reduced frequency of miniature excitatory postsynaptic currents (mEPSCs)[@electrophysiological2018]
• Decreased probability of release at corticostriatal synapses
• Impaired paired-pulse facilitation, indicating presynaptic terminal dysfunction
• Activity-dependent depression of synaptic responses in affected circuits

Post-synaptic Changes in PSP

Receptor Composition Alterations

Postsynaptic changes in PSP involve both ionotropic and metabotropic receptors:

NMDA Receptor Changes:

• Reduced NR2A/NR2B subunit ratio in affected cortical and basal ganglia regions
• Impaired NMDA receptor trafficking due to tau accumulation
• Enhanced vulnerability to excitotoxicity

• Decreased GluA1/GluA2 subunit expression in the globus pallidus
• Impaired receptor trafficking to the synaptic membrane
• Reduced synaptic conductance

• Reduced GABAA receptor density in the internal segment of the globus pallidus (GPi)[@gabaergic2018]
• Impaired inhibitory synaptic transmission
• Contributes to the characteristic movement disorders in PSP

Dendritic Spine Pathology

Tau-mediated postsynaptic damage manifests as dendritic spine loss:

• Spine density reduction: 30-50% decrease in layer V pyramidal neurons of the frontal cortex
• Morphological changes: Shift from mushroom to stubby spine phenotypes
• Dynamic alterations: Impaired spine plasticity and experience-dependent remodeling

Postsynaptic Signaling Pathway Dysruption

Tau pathology disrupts several critical postsynaptic signaling cascades:

Neurotransmitter System Dysfunction

Dopaminergic System

The dopaminergic system is severely affected in PSP:

Substantia nigra pars compacta:

• Severe loss of dopaminergic neurons (60-80% of pigmented neurons)[@dopaminergic2017]
• Synaptic loss in the nigrostriatal terminals
• Reduced tyrosine hydroxylase activity

• 40-60% reduction in dopamine transporter (DAT) binding
• Reduced vesicular monoamine transporter 2 (VMAT2)
• Correlation with parkinsonian features

• Levodopa response is typically poor in PSP compared to PD
• This reflects the extent of postsynaptic dysfunction and neuronal loss
• Dopamine receptor density is reduced in the striatum

GABAergic System

GABAergic dysfunction is prominent in PSP:

Globus pallidus internus (GPi):

• Overactivity of GPi neurons contributes to akinesia and rigidity
• Reduced GABAA receptor density on GPi neurons
• Impaired GABAergic input from the striatum

• Loss of parvalbumin-positive interneurons
• Reduced GABA release contributes to cortical hyperexcitability

• GPi deep brain stimulation can improve motor symptoms
• This reflects the functional importance of GABAergic dysfunction

Glutamatergic System

Glutamatergic neurotransmission is altered in PSP:

Cortico-striatal glutamatergic inputs:

• Impaired corticostriatal synaptic transmission
• Reduced AMPA receptor density on striatal medium spiny neurons
• Contributes to akinesia

• STN receives excitatory glutamatergic input from the cortex
• Hyperactivity of STN neurons in PSP contributes to rigidity and tremor
• Glutamatergic dysfunction correlates with falls and postural instability

• 4R tau pathology directly affects STN neurons
• Impaired mitochondrial function leads to energy failure
• Synaptic dysfunction precedes neuronal loss

Serotonergic and Noradrenergic Systems

Brainstem nuclei are affected:

Raphe nuclei:

• Serotonergic neuron loss in the dorsal raphe
• Reduced serotonin transmission contributes to depression
• Sleep disturbances may relate to serotonergic dysfunction

• Noradrenergic neuron loss
• Contributes to autonomic dysfunction
• May affect attention and arousal

Brainstem Synaptic Circuits

Oculomotor System

The oculomotor system shows particularly severe involvement in PSP:

Superior colliculus:

• 45-60% reduction in synaptophysin
• Tau pathology in the intermediate layer
• Direct correlation with vertical gaze palsy

• 40-55% synaptic marker reduction
• Tau accumulation in presynaptic terminals
• Involvement of excitatory and inhibitory synapses

• Synaptic dysfunction contributes to horizontal gaze palsy
• Disruption of saccadic burst generator neurons

Vestibular System

Brainstem vestibular circuits are affected:

• Vestibular nucleus neurons show tau pathology
• Impaired vestibular-ocular reflex (VOR)
• Contributes to postural instability and falls

Red Nucleus and Rubrospinal System

• Rubral neuron loss correlates with motor dysfunction
• Synaptic input from cerebellar nuclei is impaired
• Contributes to rigidity and axial symptoms

Electrophysiological Findings

Resting State Network Changes

Functional imaging reveals disrupted network connectivity:

• Salience network: Hyperconnectivity in early PSP
• Default mode network: Reduced connectivity in frontal regions
• Motor network: Impaired coordination between cortical and basal ganglia regions

Evoked Response Studies

Transcranial magnetic stimulation (TMS) findings:

• Reduced motor evoked potential (MEP) amplitudes
• Impaired short-interval intracortical inhibition (SICI)
• Abnormal cortical excitability patterns

EEG Findings

• Slowing of background rhythms
• Frontal delta predominance
• Correlation with cognitive impairment

Comparison with Parkinson's Disease

Shared Features

Both PSP and PD exhibit:

• Substantia nigra dopaminergic neuron loss
• Synaptic dysfunction in basal ganglia circuits
• Impaired mitochondrial function
• Protein aggregation (alpha-synuclein in PD; tau in PSP)

Key Differences

| Feature | PSP | Parkinson's Disease |
|---------|-----|---------------------|
| Protein pathology | 4R tau | Alpha-synuclein |
| Primary synaptic compartment | Both pre- and post-synaptic | Primarily presynaptic |
| Brainstem involvement | Very early, severe | Early but less severe |
| Cortical involvement | Moderate | Late |
| Lewy bodies | Absent | Present |
| Tau pathology | Primary | Incidental (in some cases) |
| Levodopa response | Poor | Good initially |
| Synaptic marker reduction | 35-55% | 25-45% |

The critical difference lies in the primary protein pathology: alpha-synuclein in PD versus 4R tau in PSP, leading to different patterns of synaptic vulnerability[@synaptic2018][@comparative2017].

Comparison with Alzheimer's Disease

Shared Features

PSP and AD both demonstrate:

• Tau pathology (though different isoforms)
• Synaptic loss that correlates with cognitive decline
• Impaired LTP and synaptic plasticity
• Dendritic spine loss

Key Differences

| Feature | PSP | Alzheimer's Disease |
|---------|-----|---------------------|
| Primary tau isoform | 4R tau | 3R + 4R tau |
| Amyloid pathology | Absent | Primary |
| Hippocampal involvement | Mild | Severe |
| Primary cognitive deficit | Executive dysfunction | Memory impairment |
| Synaptic loss pattern | Brainstem, basal ganglia | Hippocampus, cortex |
| Synaptic compartment | Primarily presynaptic | Both |

The pattern of synaptic vulnerability reflects the different regional distributions of pathology in each disease[@synaptic2018a].

Therapeutic Implications

Current Approaches

Understanding synaptic dysfunction informs therapeutic strategies:

Tau-targeted therapies:

• Tau aggregation inhibitors may reduce synaptic tau burden
• Anti-tau antibodies targeting synaptic tau
• Small molecules promoting tau clearance

• AMPA receptor modulators
• NMDA receptor modulators
• Synaptic vesicle cycle enhancers

• BDNF-based therapies
• Small molecule neurotrophin mimetics

Future Directions

Emerging approaches include:

• Gene therapy targeting synaptic proteins
• Cell-type specific delivery of neurotrophic factors
• Exercise-induced synaptic plasticity enhancement
• Synaptic regeneration strategies

Conclusion

Synaptic dysfunction in Progressive Supranuclear Palsy represents a fundamental pathological process underlying both motor and cognitive manifestations. The accumulation of 4R tau in synaptic compartments disrupts neurotransmission through multiple mechanisms, including impaired vesicle cycling, altered receptor composition, and disrupted postsynaptic signaling. The characteristic pattern of brainstem and basal ganglia synaptic vulnerability explains the classic clinical features of PSP, including vertical gaze palsy, axial rigidity, and postural instability.

Comparison with other neurodegenerative disorders reveals both shared mechanisms and disease-specific patterns. The predominance of tau pathology provides unique insights into tau-specific synaptic toxicity, complementing knowledge gained from alpha-synucleinopathies like PD and amyloid-driven disorders like AD. Understanding these mechanisms offers opportunities for developing targeted therapies that may prove beneficial across the tauopathy spectrum.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References